Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ: NBTX )

3.250 +0.220 (+7.26%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nanobiotix S.A. - ADSs

< Previous 1 2 3 4 5 Next >
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology
From NANOBIOTIX
Via Business Wire
NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect
From NANOBIOTIX
Via Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital as of August 31, 2021
From Nanobiotix
Via Business Wire
NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021
From NANOBIOTIX S.A.
Via Business Wire
Nanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From NANOBIOTIX
Via Business Wire
Nanobiotix Provides Second Quarter Operational and Financial Update
From NANOBIOTIX
Via Business Wire
NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
From NANOBIOTIX
Via Business Wire
NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021
From NANOBIOTIX
Via Business Wire
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure
From NANOBIOTIX
Via Business Wire
NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion
From NANOBIOTIX
Via Business Wire
NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
From NANOBIOTIX
Via Business Wire
Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board
From Nanobiotix
Via Business Wire
CORRECTING and REPLACING Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology
From Nanobiotix
Via Business Wire
Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology
From Nanobiotix
Via Business Wire
Nanobiotix to Present at the UBS Global Healthcare Virtual Conference
From Nanobiotix
Via Business Wire
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets
From NANOBIOTIX
Via Business Wire
NANOBIOTIX Announces First Quarter Operational and Financial Updates
From NANOBIOTIX
Via Business Wire
NANOBIOTIX to Present Four Posters Including Updates From Priority Head and Neck Cancer and Immunotherapy Development Pathways at the 2021 Annual Meeting of the American Society for Clinical Oncology
From NANOBIOTIX
Via Business Wire
Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021
From Nanobiotix
Via Business Wire
NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
From NANOBIOTIX
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.